422 related articles for article (PubMed ID: 30389552)
21. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
22. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
23. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
[TBL] [Abstract][Full Text] [Related]
24. Irisin expression and
Foad AM; Hafez A; Youssef W; Ahmed AE; Altaher AM
Arch Physiol Biochem; 2023 Feb; ():1-6. PubMed ID: 36732920
[TBL] [Abstract][Full Text] [Related]
25. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver.
Alam S; Islam MS; Islam S; Mustafa G; Saleh AA; Ahmad N
Indian J Gastroenterol; 2017 Sep; 36(5):366-372. PubMed ID: 28975533
[TBL] [Abstract][Full Text] [Related]
26. Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients.
Liu WY; Zhang X; Li G; Tang LJ; Zhu PW; Rios RS; Zheng KI; Ma HL; Wang XD; Pan Q; de Knegt RJ; Valenti L; Ghanbari M; Zheng MH
Clin Mol Hepatol; 2022 Apr; 28(2):183-195. PubMed ID: 34839623
[TBL] [Abstract][Full Text] [Related]
27. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease.
Bugianesi E; Bizzarri C; Rosso C; Mosca A; Panera N; Veraldi S; Dotta A; Giannone G; Raponi M; Cappa M; Alisi A; Nobili V
Am J Gastroenterol; 2017 Aug; 112(8):1277-1286. PubMed ID: 28555633
[TBL] [Abstract][Full Text] [Related]
28. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
[TBL] [Abstract][Full Text] [Related]
29. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise.
Huh JY; Panagiotou G; Mougios V; Brinkoetter M; Vamvini MT; Schneider BE; Mantzoros CS
Metabolism; 2012 Dec; 61(12):1725-38. PubMed ID: 23018146
[TBL] [Abstract][Full Text] [Related]
30. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
Baselli GA; Dongiovanni P; Rametta R; Meroni M; Pelusi S; Maggioni M; Badiali S; Pingitore P; Maurotti S; Montalcini T; Taliento AE; Prati D; Rossi G; Fracanzani AL; Mancina RM; Romeo S; Valenti L
Gut; 2020 Oct; 69(10):1855-1866. PubMed ID: 32001554
[TBL] [Abstract][Full Text] [Related]
31. miR-3666 inhibits development of hepatic steatosis by negatively regulating PPARγ.
Mittal S; Inamdar S; Acharya J; Pekhale K; Kalamkar S; Boppana R; Ghaskadbi S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158777. PubMed ID: 32755726
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
33. The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties.
Wang X; Mao L; Li C; Hui Y; Yu Z; Sun M; Li Y; Guo G; Yang W; Cui B; Fan X; Sun C
Expert Rev Mol Med; 2022 Jun; 24():e23. PubMed ID: 35695040
[TBL] [Abstract][Full Text] [Related]
34. Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.
Hanson A; Piras IS; Wilhelmsen D; Still CD; Chu X; Petrick A; Gerhard GS; DiStefano JK
Cytokine; 2019 Nov; 123():154789. PubMed ID: 31352173
[TBL] [Abstract][Full Text] [Related]
35. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
36. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
37. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
38. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
39. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
40. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
